1. Home
  2. MEOH vs ICUI Comparison

MEOH vs ICUI Comparison

Compare MEOH & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Methanex Corporation

MEOH

Methanex Corporation

HOLD

Current Price

$54.38

Market Cap

3.7B

Sector

Industrials

ML Signal

HOLD

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$166.37

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEOH
ICUI
Founded
1968
1984
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.6B
IPO Year
1995
1995

Fundamental Metrics

Financial Performance
Metric
MEOH
ICUI
Price
$54.38
$166.37
Analyst Decision
Buy
Strong Buy
Analyst Count
9
3
Target Price
$58.33
$169.00
AVG Volume (30 Days)
998.9K
271.4K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
1.17%
N/A
EPS Growth
N/A
100.62
EPS
N/A
1.20
Revenue
N/A
$2,231,262,000.00
Revenue This Year
$25.43
N/A
Revenue Next Year
N/A
$4.46
P/E Ratio
$16.44
$138.67
Revenue Growth
N/A
N/A
52 Week Low
$32.00
$107.02
52 Week High
$66.75
$176.27

Technical Indicators

Market Signals
Indicator
MEOH
ICUI
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
MEOH
ICUI

About MEOH Methanex Corporation

Methanex Corp operates as a producer and supplier of methanol to various international markets in North America, Asia Pacific, Europe and South America. The company's operations consist prominently of the production and sale of methanol, along with the production and sale of ammonia. Geographically, it operates in China, Europe, the United States, South America, South Korea, Other Asia, and Canada. The majority of revenue is derived from Europe.

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

Share on Social Networks: